TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET
Company Participants
Michael Weiss - Chairman, Chief Executive Officer
Adam Waldman - Chief Commercialization Officer
Sean Power - Chief Financial Officer
Jenna Bosco - Senior Vice President of Corporate Communications
Conference Call Participants
Roger Song - Jefferies
Matt Kaplan - Ladenburg Thalmann
Michael DiFiore - Evercore ISI
Eric Joseph - JP Morgan
Mayank Mamtani - B. Riley Securities
Prakhar Agrawal - Cantor Fitzgerald
Ed White - H.C. Wainwright
Operator
Greetings. Welcome to TG Therapeutics’ Conference Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded.
I'll now turn the conference over to Jenna Bosco. Jenna, you may begin.
Jenna Bosco
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco and with me today to discuss the second quarter 2024 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer.
Following our Safe Harbor statement, Mike will provide an overview of our recent corporate development, Adam will share an update on our commercialization efforts and Sean will give an overview of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I'd like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, including sales performance, projected regulatory or clinical milestones, revenue guidance, development plans and expectations for our marketed products.
TG cautions that these forward-looking statements are subject to risks that may cause our actual results to differ materially from those indicated. Factors that may affect TG Therapeutics operations include various risk factors that can be found in our SEC filings. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any later date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on TG's website, www.tgtherapeutics.com, where it will be available for the next 30 days.
With that, I'd like to turn the call over to Mike Weiss, our CEO.